Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06131840 · ClinicalTrials.gov registry record · Phase 1

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Ductal Adenocarcinoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

Recruiting
Registry status
Phase 1
Development phase
914
Enrollment target
20
Study locations

NCT06131840 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 914 participants, above the 317-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (188% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06131840, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Seagen, a wholly owned subsidiary of Pfizer.

RECRUITING
Registry status
Phase 1
Development phase
914 participants
Enrollment target
20
Study locations

Study Summary

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Participants in this study must have cancer that has come back or did not get better with treatment. Participants must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08046050. PF-08046050 is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of PF-08046050 in participants with solid tumors that are hard to treat or have spread throughout the body. This study has 5 different study parts. Part A and Part B of the study will find out how much PF-08046050 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046050 is safe and if it works to treat certain solid tumor cancers. Part D and E of the study, together with information from Parts A and B, will find out how much PF-08046050 should be given in combination with other anti-cancer agents. Part E will use the information from Parts A, B, and D to see if PF-08046050 is safe in combination with other anti-cancer agents and if it works to treat a certain solid tumor.

Conditions Studied

Carcinoma, Non-Small Cell Lung Pancreatic Ductal Adenocarcinoma Colorectal Neoplasms Gastroesophageal Junction Adenocarcinoma Small Cell Lung Carcinoma Stomach Neoplasms

Interventions

  • DRUG 5-Fluorouracil (5-FU)
  • DRUG Oxaliplatin
  • DRUG PF-08046050
  • DRUG bevacizumab
  • DRUG Leucovorin (LV)

Study Locations (20)

Arizona

  • Mayo Clinic Hospital - Phoenix
  • Mayo Clinic - Scottsdale

California

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center) - Duarte
  • IP Address: City of Hope Investigational Drug Services(IDS) - Duarte

Colorado

  • University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) - Aurora
  • University of Colorado Hospital - Aurora

Florida

  • Florida Cancer Specialists - Orlando
  • Sarah Cannon Research Institute at Florida Cancer Specialists - Orlando

Maryland

  • Sidney Kimmel Comprehensive Cancer at Johns Hopkins - Baltimore
  • The Johns Hopkins University - Baltimore

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Beth Israel Deaconess Medical Center - Boston

Minnesota

  • Mayo Clinic Cancer Center - Rochester
  • Mayo Clinic - Rochester

Tennessee

  • Sarah Cannon Research Institute - Pharmacy - Nashville
  • SCRI Oncology Partners - Nashville

Trial Details

FieldValue
Enrollment Target 914 participants
Start Date 2023-11-20
Est. Completion 2030-09-12
Phase Phase 1

Sponsor

Seagen, a wholly owned subsidiary of Pfizer

28 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06131840

The ClinicalTrials.gov registry entry for NCT06131840 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 914 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 317-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (188% higher). The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which 5-Fluorouracil (5-FU) is the first listed.

NCT06131840 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Arizona, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT06131840 about?

NCT06131840 is a clinical study titled "A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors". This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts o...

What is the current status of trial NCT06131840?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 914 participants. The study started on 2023-11-20. Estimated completion is 2030-09-12.

What conditions does trial NCT06131840 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Pancreatic Ductal Adenocarcinoma, Colorectal Neoplasms, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma.

What interventions are being tested in trial NCT06131840?

The interventions under investigation include: 5-Fluorouracil (5-FU) (DRUG), Oxaliplatin (DRUG), PF-08046050 (DRUG), bevacizumab (DRUG), Leucovorin (LV) (DRUG).

Who is sponsoring clinical trial NCT06131840?

This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06131840 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.